Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) Director William Waddill sold 9,000 shares of the stock in a transaction on Wednesday, June 10th. The shares were sold at an average price of $107.68, for a total transaction of $969,120.00. Following the transaction, the director directly owned 7,825 shares in the company, valued at approximately $842,596. The trade was a 53.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Protagonist Therapeutics Stock Down 0.0%
PTGX opened at $109.78 on Friday. The company has a market cap of $7.06 billion, a price-to-earnings ratio of -60.65 and a beta of 1.85. Protagonist Therapeutics, Inc. has a 52-week low of $49.38 and a 52-week high of $111.78. The firm’s fifty day simple moving average is $101.71 and its two-hundred day simple moving average is $93.22.
Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.55. The business had revenue of $56.37 million for the quarter, compared to the consensus estimate of $11.70 million. Protagonist Therapeutics had a negative net margin of 154.88% and a negative return on equity of 17.76%. On average, research analysts forecast that Protagonist Therapeutics, Inc. will post 2.93 EPS for the current year.
Institutional Investors Weigh In On Protagonist Therapeutics
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently commented on the stock. Truist Financial increased their target price on shares of Protagonist Therapeutics from $110.00 to $121.00 and gave the company a “buy” rating in a research report on Tuesday, April 14th. TD Cowen increased their target price on shares of Protagonist Therapeutics from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Wedbush increased their target price on shares of Protagonist Therapeutics from $112.00 to $118.00 and gave the company an “outperform” rating in a research report on Wednesday, May 6th. Jefferies Financial Group reiterated a “buy” rating and issued a $121.00 target price on shares of Protagonist Therapeutics in a research report on Wednesday, March 18th. Finally, Wolfe Research assumed coverage on shares of Protagonist Therapeutics in a research report on Thursday, May 21st. They issued an “outperform” rating and a $135.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Protagonist Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $115.21.
View Our Latest Research Report on Protagonist Therapeutics
Protagonist Therapeutics Company Profile
Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.
Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.
Further Reading
- Five stocks we like better than Protagonist Therapeutics
- SpaceX Rings the Bell and Shatters Every Record
- Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?
- 3 Dividend Stocks Under $50 That Pay You to Wait Out Inflation
- The 127-Gigawatt Problem: Why AI Needs Its Own Power
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
